|
Polycystic Ovary Syndrome
|
0.520 |
GeneticVariation
|
disease |
BEFREE |
Carrying the HSD3B1 1245C allele and overweight are associated with the presence of female pattern hair loss in women with polycystic ovary syndrome.
|
31056381 |
2019 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
HSD3B1 Genotypes Conferring Adrenal-Restrictive and Adrenal-Permissive Phenotypes in Prostate Cancer and Beyond.
|
31271415 |
2019 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
HSD3B1 Genotypes Conferring Adrenal-Restrictive and Adrenal-Permissive Phenotypes in Prostate Cancer and Beyond.
|
31271415 |
2019 |
|
Hormone refractory prostate cancer
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
Herein, we review current knowledge of the mechanisms conferred by HSD3B1 genotype to alter androgen physiology and accelerate development of castration-resistant disease and its associations with clinical PCa outcomes.
|
31271415 |
2019 |
|
Hormone refractory prostate cancer
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
The variant allele 1245C of the HSD3B1 gene is present in approximately one-half of patients with CRPC; however, it is not associated with oncologic outcomes.
|
31331867 |
2019 |
|
Neoplasms
|
0.040 |
GeneticVariation
|
group |
BEFREE |
This study presents a comprehensive assessment of germline variants in androgen metabolism genes and highlights HSD3B1 polymorphisms as prognostic of OS after ADT and associated with an aggressive gene expression tumor profile in mCRPC.
|
31745256 |
2019 |
|
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
Recently, we demonstrated that the expression of 3β-hydroxysteroid dehydrogenase type 1 (HSD3B1) in breast cancer is associated with shorter recurrence-free survival, and genetic or pharmacologic inhibition of HSD3B1 reduced colony formation and xenograft growth.However, the mechanisms are unclear.
|
31004874 |
2019 |
|
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Recently, we demonstrated that the expression of 3β-hydroxysteroid dehydrogenase type 1 (HSD3B1) in breast cancer is associated with shorter recurrence-free survival, and genetic or pharmacologic inhibition of HSD3B1 reduced colony formation and xenograft growth.However, the mechanisms are unclear.
|
31004874 |
2019 |
|
Neoplasm Metastasis
|
0.020 |
GeneticVariation
|
phenotype |
BEFREE |
Consistent with this mechanism, this adrenal-permissive HSD3B1(1245C) genotype is associated with inferior outcomes after androgen deprivation therapy for advanced PCa, and increased sensitivity to pharmacologic blockade of adrenal precursors in metastatic disease.
|
31271415 |
2019 |
|
Metastatic castration-resistant prostate cancer
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
This study presents a comprehensive assessment of germline variants in androgen metabolism genes and highlights HSD3B1 polymorphisms as prognostic of OS after ADT and associated with an aggressive gene expression tumor profile in mCRPC.
|
31745256 |
2019 |
|
Alopecia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Carrying the HSD3B1 1245C allele and overweight are associated with the presence of female pattern hair loss in women with polycystic ovary syndrome.
|
31056381 |
2019 |
|
early pregnancy
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
The mRNA expression of cytochrome P450 family 11 subfamily A member 1 and hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 was analyzed using real-time PCR, while progesterone concentration in culture medium was assessed by radioimmunoassay.Dynamic changes of prostacyclin synthase and prostacyclin receptor expression were observed in porcine luteal tissue during the estrous cycle and early pregnancy.
|
30481284 |
2019 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
AR Signaling in Prostate Cancer Regulates a Feed-Forward Mechanism of Androgen Synthesis by Way of HSD3B1 Upregulation.
|
29850791 |
2018 |
|
Malignant neoplasm of prostate
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In this study, the HSD3B1 (1245C) allele was associated with more rapid development of metastases in men treated with ADT for biochemical recurrence after primary radiation therapy for prostate cancer.
|
29049492 |
2018 |
|
Malignant neoplasm of prostate
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We hypothesized that the HSD3B1 (1245C) variant predicts response to treatment with abiraterone acetate (AA) and can help personalize treatment in men with advanced prostate cancer.
|
29674118 |
2018 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer.
|
29231195 |
2018 |
|
Malignant neoplasm of prostate
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer.
|
29939161 |
2018 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We hypothesized that the HSD3B1 (1245C) variant predicts response to treatment with abiraterone acetate (AA) and can help personalize treatment in men with advanced prostate cancer.
|
29674118 |
2018 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer.
|
29231195 |
2018 |
|
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
AR Signaling in Prostate Cancer Regulates a Feed-Forward Mechanism of Androgen Synthesis by Way of HSD3B1 Upregulation.
|
29850791 |
2018 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, the HSD3B1 (1245C) allele was associated with more rapid development of metastases in men treated with ADT for biochemical recurrence after primary radiation therapy for prostate cancer.
|
29049492 |
2018 |
|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer.
|
29939161 |
2018 |
|
Hormone refractory prostate cancer
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
To determine whether the HSD3B1 (1245C) genotype is predictive of clinical response to extragonadal androgen ablation with nonsteroidal 17α-hydroxylase/17,20-lyase (CYP17A1) inhibition in men with metastatic CRPC.
|
29049452 |
2018 |
|
Hormone refractory prostate cancer
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
The HSD3B1 (1245C) variant also predicts longer duration of response to ketoconazole in men with castration-resistant prostate cancer (CRPC).
|
29674118 |
2018 |
|
Neoplasms
|
0.040 |
GeneticVariation
|
group |
BEFREE |
In addition, inheritance of the HSD3B1 variant is associated with extended responses to 17α-hydroxylase/17,20-lyase (CYP17A1) inhibition with a nonsteroidal agent, adding to evidence of increased tumour dependence on extragonadal androgens in patients who inherited the HSD3B1 variant.
|
29231195 |
2018 |